Our finding that PLK1 inhibition combined with erlotinib could overcome the EGFR-TKI resistance with T790M mutation will provide new treatment strategy for the acquired EGFR-TKI resistance in NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.